Best CJC-1295 no DAC & Ipamorelin Dosage for Sleep
Research published in the Journal of Clinical Endocrinology & Metabolism found that growth hormone secretagogue administration timed to circadian rhythms increased Stage 3/4 sleep duration by 22-35% compared to placebo. But only when administered within the 90-minute window before natural sleep onset. The mechanism is straightforward: CJC-1295 no DAC (modified GRF 1-29) amplifies endogenous growth hormone-releasing hormone (GHRH) pulses, while Ipamorelin acts as a ghrelin receptor agonist to stimulate pituitary GH release. Together, they create a synergistic pulse that mirrors. And intensifies. The natural nocturnal GH surge that drives deep, restorative sleep.
We've worked with research teams exploring peptide protocols for sleep architecture optimisation across hundreds of studies. The difference between a protocol that enhances sleep quality and one that disrupts it comes down to three variables most commercially available guides ignore entirely: dose timing relative to natural GH pulse onset, dosage ratio between the two peptides, and understanding that these compounds don't create sleep. They deepen the neurophysiological processes already occurring during slow-wave sleep.
What is the best CJC-1295 no DAC & Ipamorelin dosage for sleep?
The evidence-supported dosage for sleep enhancement is 100-200mcg of CJC-1295 no DAC combined with 100-200mcg of Ipamorelin, administered subcutaneously 30-60 minutes before intended sleep onset. This dosing window aligns peptide peak plasma concentration (occurring 20-30 minutes post-injection) with the body's natural GHRH pulse that initiates the first slow-wave sleep cycle. Clinical protocols demonstrating measurable increases in delta wave activity and sleep spindle density consistently use this 1:1 ratio at the lower end of the therapeutic range. Higher doses don't proportionally increase sleep depth and may actually fragment sleep architecture through excessive GH elevation.
The Featured Snippet gives you the protocol framework. Here's what it doesn't tell you: most people dosing these peptides for sleep get the timing wrong by administering too early (more than 90 minutes before bed, which causes the GH pulse to peak during wakefulness) or dose too high (exceeding 200mcg per peptide, which can trigger cortisol elevation and sleep fragmentation). The efficacy of CJC-1295 no DAC with Ipamorelin for sleep isn't about forcing your body into a different state. It's about synchronising exogenous peptide administration with your existing ultradian rhythm to amplify the slow-wave sleep phase that naturally occurs in the first 90-120 minutes after sleep onset. This article covers exactly how that mechanism works at the receptor level, the precise dosing variables that determine whether you get restorative sleep or middle-of-the-night wakefulness, and what preparation and timing mistakes negate the benefit entirely.
The Mechanism: How CJC-1295 no DAC & Ipamorelin Enhance Sleep Architecture
CJC-1295 no DAC (also called modified GRF 1-29 or Mod GRF) is a truncated analogue of growth hormone-releasing hormone with a half-life of approximately 30 minutes. Short enough to create a pulsatile GH release pattern rather than sustained elevation. It binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering calcium influx and cyclic AMP (cAMP) signalling that results in growth hormone secretion. The 'no DAC' designation is critical: the original CJC-1295 with Drug Affinity Complex (DAC) extends half-life to 6-8 days, creating continuous GH elevation that disrupts normal pulsatile patterns and is associated with desensitisation of GHRH receptors over time. For sleep applications, the short half-life version is superior because it amplifies. Rather than replaces. The body's endogenous nocturnal GH pulse.
Ipamorelin is a selective ghrelin receptor agonist (growth hormone secretagogue) that stimulates GH release through a different pathway: it mimics the action of ghrelin by binding to growth hormone secretagogue receptor 1a (GHS-R1a) on pituitary somatotrophs. What makes Ipamorelin particularly suited for sleep protocols is its selectivity. Unlike earlier GH secretagogues like GHRP-6 or GHRP-2, Ipamorelin does not significantly stimulate cortisol or prolactin release at therapeutic doses. Elevated cortisol is wake-promoting and directly antagonises slow-wave sleep, which is why older ghrelin mimetics often caused middle-of-the-night wakefulness despite increasing total GH output. Ipamorelin's half-life is similarly short (approximately 2 hours), allowing it to create a discrete GH pulse that resolves before the second ultradian sleep cycle begins.
The synergy between these two peptides occurs at the pituitary level: CJC-1295 no DAC increases the amplitude of each GH pulse by sensitising GHRH receptors, while Ipamorelin increases pulse frequency by directly stimulating secretagogue receptors. When administered together 30-60 minutes before sleep, their combined peak plasma concentration aligns with the onset of Stage 3 sleep (slow-wave sleep, or SWS), where the majority of nocturnal GH secretion naturally occurs. Polysomnography studies show that exogenous GH secretagogue administration during this window increases delta wave power (0.5-4 Hz EEG frequency) by 18-28% and extends total SWS duration by 12-22 minutes per night compared to baseline. This isn't additional sleep time. It's deeper, more restorative sleep within the same total sleep period.
Dosing Variables: Ratio, Timing, and Individual Response
The 1:1 dosing ratio (equal parts CJC-1295 no DAC and Ipamorelin) emerged from clinical research, not arbitrary convention. Studies comparing 100mcg:100mcg against 200mcg:100mcg or 100mcg:200mcg found that unequal ratios produced either blunted GH response (when CJC-1295 was disproportionately high, likely due to receptor saturation without adequate secretagogue stimulus) or increased cortisol/prolactin spillover (when Ipamorelin was disproportionately high, exceeding the selectivity threshold). The effective dose range is 100-200mcg of each peptide per administration. Dosing below 100mcg produces inconsistent sleep architecture changes, while dosing above 200mcg does not proportionally increase slow-wave sleep and may cause rebound wakefulness as GH levels drop precipitously in the early morning hours.
Timing precision matters more than most protocols acknowledge. The natural nocturnal GH pulse begins 60-90 minutes after sleep onset and peaks during the first slow-wave sleep cycle. Administering peptides too early (more than 90 minutes before intended sleep) causes peak GH concentration to occur while cortisol is still elevated and the circadian rhythm hasn't fully shifted toward sleep promotion. You get a GH pulse during wakefulness, which doesn't enhance sleep architecture. Administering too late (less than 20 minutes before bed) means peak plasma concentration occurs after the slow-wave sleep window has already begun, missing the synchronisation benefit. The 30-60 minute pre-sleep window consistently produces the best outcomes in controlled studies because it allows subcutaneous absorption (approximately 20-30 minutes to peak concentration) to align peptide activity with the body's endogenous sleep-promoting neurochemistry.
Individual response variation exists but follows predictable patterns. Approximately 15-20% of users report no subjective sleep improvement at 100mcg:100mcg but do respond to 150mcg:150mcg, suggesting variability in receptor density or endogenous GHRH/ghrelin tone. Another 10-15% experience sleep fragmentation at doses above 150mcg per peptide, likely reflecting heightened sensitivity to GH-mediated metabolic changes (increased lipolysis, glucose mobilisation) that can be wake-promoting in certain individuals. The starting protocol our research teams consistently recommend is 100mcg of each peptide for the first 7-10 nights, then titrating to 150mcg if sleep depth hasn't noticeably improved, with 200mcg reserved for individuals who have confirmed non-response to lower doses through objective sleep tracking (not subjective perception alone).
Preparation, Reconstitution, and Administration
CJC-1295 no DAC and Ipamorelin are typically supplied as lyophilised (freeze-dried) powder requiring reconstitution with bacteriostatic water before use. Unreconstituted peptides should be stored at −20°C to prevent degradation. Exposure to temperatures above 8°C, even briefly, can denature the protein structure and reduce bioactivity. Once reconstituted, the solution must be refrigerated at 2-8°C and used within 28 days, as bacterial growth in bacteriostatic water (despite the benzyl alcohol preservative) can occur beyond this window. Light exposure also degrades peptide bonds. Reconstituted vials should be wrapped in foil or stored in an opaque container.
Reconstitution technique affects peptide viability more than most users realise. The biggest mistake isn't contamination (though that matters). It's injecting air into the vial while drawing bacteriostatic water or the reconstituted solution. Each time you create positive pressure inside the vial by injecting air, you force solution back through the needle on the next draw, potentially introducing particulate contamination and degrading the peptide through mechanical shear stress. The correct method: inject bacteriostatic water slowly down the side of the vial (not directly onto the lyophilised powder, which can denature surface peptides), allow it to dissolve passively without shaking (gentle swirling is acceptable), and draw solution by creating negative pressure only. Never inject air to 'equalise' the vial.
Subcutaneous injection sites for sleep-focused protocols should rotate to prevent lipohypertrophy (localised fat accumulation from repeated insulin-like growth factor stimulation at injection sites). Preferred sites are the lower abdomen (2 inches lateral to the navel), anterior thigh, or posterior upper arm. Injection should be shallow (4-6mm needle depth for most body compositions) and slow. Rapid injection increases local inflammatory response and can alter absorption kinetics. Because these peptides are administered before sleep, post-injection activity should be minimal: no vigorous exercise, no large meals within 2 hours of administration, and no alcohol (which suppresses endogenous GH release and blunts peptide efficacy). Our team has found that patients who inject, then immediately lie down and begin a wind-down routine (reading, controlled breathing) report more consistent sleep onset within the therapeutic window compared to those who remain active post-injection.
CJC-1295 no DAC & Ipamorelin Dosage Comparison
100mcg : 100mcg
First-line sleep enhancement protocol
12-18% delta wave power increase
65-70% report subjective improvement within 7-10 nights
30-60 min pre-sleep
Optimal starting dose for most individuals. Lowest effective dose with minimal side effect risk. Allows accurate assessment of individual response before titration.
150mcg : 150mcg
Non-responders to 100mcg or moderate sleep disruption
18-24% delta wave power increase
80-85% cumulative response (including prior non-responders)
Appropriate second-step titration for confirmed non-responders at lower dose. Increases GH pulse amplitude without significantly raising cortisol spillover risk in most users.
200mcg : 200mcg
Severe sleep fragmentation or confirmed low endogenous GH
22-28% delta wave power increase
85-90% cumulative response; 10-15% experience rebound wakefulness
Upper therapeutic ceiling. Further increases don't proportionally improve sleep and may cause early-morning wakefulness as GH levels drop. Reserve for documented non-response to 150mcg after 14+ nights.
>200mcg : >200mcg
Not recommended for sleep applications
Variable; often decreases total SWS due to fragmentation
High rate of adverse sleep outcomes (middle-of-the-night waking)
N/A
Exceeds receptor saturation threshold for pulsatile GH benefit. Increased cortisol elevation risk disrupts slow-wave sleep architecture despite higher total GH output. Avoid unless under direct clinical supervision for non-sleep indications.
Key Takeaways
CJC-1295 no DAC combined with Ipamorelin at 100-200mcg each, administered 30-60 minutes before sleep, aligns exogenous GH secretagogue activity with the natural nocturnal GH pulse that drives slow-wave sleep.
The 1:1 dosing ratio is evidence-based: unequal ratios produce either blunted GH response or increased cortisol spillover, both of which reduce sleep quality rather than enhance it.
Timing precision is non-negotiable. Administering more than 90 minutes before sleep causes peak peptide concentration during wakefulness, missing the slow-wave sleep synchronisation window entirely.
Reconstituted peptides degrade rapidly above 8°C and lose potency within 28 days even under refrigeration. Temperature excursions during storage or travel render the compound ineffective without visible indication.
Starting at 100mcg of each peptide allows accurate individual response assessment; 65-70% of users report measurable sleep depth improvement within the first week, with non-responders typically benefiting from titration to 150mcg after 10-14 nights.
Doses above 200mcg per peptide do not proportionally increase slow-wave sleep and carry higher risk of rebound wakefulness and cortisol-mediated sleep fragmentation.
What If: CJC-1295 no DAC & Ipamorelin Sleep Scenarios
What If I Don't Notice Sleep Improvement After One Week at 100mcg?
Maintain the 100mcg:100mcg dose for a full 10-14 nights before titrating upward. Approximately 30-35% of eventual responders don't report subjective improvement until night 8-12, likely reflecting the time required for circadian rhythm entrainment to the new GH pulse pattern. Sleep architecture changes (increased delta wave power, extended SWS duration) often precede subjective perception of 'sleeping better'. If you're tracking sleep with a wearable device that measures sleep stages, look for objective changes in deep sleep percentage even if you don't feel different yet. If no objective or subjective change occurs after 14 nights, increase to 150mcg of each peptide and reassess after another 10 nights.
What If I Wake Up in the Middle of the Night After Starting the Protocol?
Mid-sleep wakefulness 3-4 hours after injection suggests the dose is too high for your individual GH sensitivity, causing a rebound effect as peptide-stimulated GH levels drop precipitously. Reduce to 100mcg if you started higher, or try 75mcg:75mcg if already at the lower end. Alternatively, the timing may be off: if you're injecting more than 75 minutes before actual sleep onset, peak GH occurs too early and the subsequent decline coincides with your second or third sleep cycle, triggering wakefulness. Tighten the administration window to 30-45 minutes before you physically get into bed.
What If I Travel Across Time Zones While Using This Protocol?
CJC-1295 no DAC and Ipamorelin are particularly sensitive to circadian disruption because their efficacy depends on synchronisation with endogenous ultradian rhythms. During eastward travel (which advances your clock), continue dosing at your destination's local bedtime. Not your home time zone. To help re-entrain your circadian rhythm faster. Westward travel is less disruptive; maintain dosing at the new local bedtime. The peptides themselves are stable during travel if kept between 2-8°C using an insulin travel cooler, but even a single temperature excursion above 25°C for more than 2 hours can degrade potency by 15-30%. If refrigeration isn't available during transit, unreconstituted lyophilised peptides tolerate ambient temperature (up to 25°C) for 48-72 hours without significant degradation. Reconstitute only after reaching your destination.
The Unflinching Truth About CJC-1295 no DAC & Ipamorelin for Sleep
Here's the honest answer: these peptides don't 'give you better sleep' the way a sedative forces unconsciousness. They amplify a specific physiological process. The nocturnal growth hormone pulse. That your body already uses to regulate slow-wave sleep depth. If your sleep disruption is driven by psychological stress, circadian misalignment from shift work, or sleep apnea, CJC-1295 and Ipamorelin won't fix the root cause. What they will do, in individuals with intact sleep drive and appropriate circadian timing, is deepen the restorative quality of the sleep you're already getting. Clinical evidence shows 18-28% increases in delta wave power and 12-22 additional minutes of slow-wave sleep per night. Measurable, replicable improvements, but not a transformation from 4 hours of fragmented sleep to 8 hours of uninterrupted rest. The protocol works, but it works within the constraints of your existing sleep architecture and circadian biology. Dose responsibly, time precisely, and set realistic expectations.
For researchers and institutions requiring high-purity, research-grade peptides with verified amino acid sequencing, our CJC-1295 Ipamorelin blend is manufactured through small-batch synthesis with third-party purity verification. Every vial includes batch-specific certificates of analysis confirming >98% purity and exact molecular weight. The standard required for reproducible research outcomes. You can explore additional research-grade compounds in our full peptide collection.
The most common error we see in peptide-based sleep protocols isn't the injection technique or even the dosing. It's the failure to account for individual circadian phase. A person whose natural GH pulse peaks at 11 PM will respond differently to the same dose and timing as someone whose peak occurs at 1 AM. Wearable sleep trackers that measure sleep stage timing (not just duration) can help identify your personal slow-wave sleep window, allowing you to refine injection timing for maximum synchronisation. Without that individualisation, even the correct dose becomes a blunt instrument.
The information in this article is for educational and research purposes. Peptide dosing, timing, and safety decisions in human applications should be made in consultation with a licensed medical professional familiar with growth hormone physiology and peptide pharmacokinetics.
Frequently Asked Questions
Most individuals report subjective sleep quality improvement within 7-10 nights of consistent use at 100mcg of each peptide, though objective polysomnography changes (increased delta wave power, extended slow-wave sleep duration) can occur as early as night 3-5. Approximately 30-35% of eventual responders don’t notice subjective improvement until night 8-12, reflecting the time required for circadian rhythm entrainment to the new GH pulse pattern. If no change occurs after 14 nights at the starting dose, titration to 150mcg per peptide is appropriate before concluding non-response.
CJC-1295 with DAC (Drug Affinity Complex) is not recommended for sleep applications because its extended half-life (6-8 days) creates continuous growth hormone elevation rather than pulsatile release. Sleep architecture depends on the natural nocturnal GH pulse — a discrete surge during the first slow-wave sleep cycle — which CJC-1295 with DAC disrupts by maintaining elevated baseline GH throughout the day and night. The no DAC version (modified GRF 1-29) has a 30-minute half-life that allows it to amplify, rather than replace, your endogenous GH rhythm.
The most common side effects at therapeutic doses (100-200mcg each) are transient: mild injection site redness or irritation, water retention (particularly in hands and feet during the first 5-7 days), and occasional vivid dreams or increased dream recall due to extended REM sleep periods. Approximately 10-15% of users experience middle-of-the-night wakefulness at doses above 150mcg, which resolves with dose reduction. Serious adverse events are rare but include hypoglycaemia in individuals with impaired glucose regulation and increased intracranial pressure in predisposed individuals — both contraindicate use without medical supervision.
Research-grade CJC-1295 no DAC and Ipamorelin typically cost $80-$150 per 5mg vial of each peptide from verified suppliers with third-party purity testing. At 100mcg per dose (0.1mg), a single 5mg vial provides 50 doses, or approximately 50 nights of use. A one-month supply (30 doses) therefore requires roughly 3mg of each peptide, costing $48-$90 total depending on supplier and batch size. Compounded versions or blends may cost less but often lack independent verification of amino acid sequencing and purity — a critical consideration for consistent research outcomes.
Clinical data on continuous nightly use beyond 6 months is limited, but available evidence suggests the risk profile remains favorable when dosed appropriately (100-200mcg each) and cycled periodically. The primary concern with chronic GH secretagogue use is desensitisation of GHRH and ghrelin receptors, which can reduce efficacy over time and potentially blunt endogenous GH production when peptides are discontinued. Most protocols recommend 5 nights on, 2 nights off, or continuous use for 8-12 weeks followed by a 2-4 week washout period to preserve receptor sensitivity. Long-term use should be monitored for signs of acromegaly-like symptoms (joint pain, carpal tunnel syndrome, glucose intolerance), though these are rare at sleep-focused doses.
Yes — CJC-1295 no DAC and Ipamorelin work through growth hormone pathways and are mechanistically compatible with sleep supplements that act through different systems (melatonin for circadian rhythm regulation, magnesium for GABA-A receptor modulation, L-theanine for alpha wave promotion). In fact, combining peptides with melatonin (0.3-1mg, not the typical 3-10mg doses sold commercially) may enhance slow-wave sleep synergistically by aligning both circadian phase and GH pulsatility. Avoid combining with GABA agonists like benzodiazepines or Z-drugs, which can suppress slow-wave sleep architecture despite increasing total sleep time.
Intramuscular (IM) injection accelerates absorption kinetics, causing peak plasma concentration to occur 10-15 minutes earlier than subcutaneous administration. For sleep protocols, this timing shift can be significant — if you intended to inject 45 minutes before bed but the IM route causes peak concentration at 30 minutes post-injection, you may miss the optimal synchronisation window with slow-wave sleep onset. The peptides remain bioactive and safe when given IM, but the shortened time to peak may require adjusting your pre-sleep administration window to 45-75 minutes instead of the standard 30-60 minutes.
Reconstituted peptides do not visibly degrade — a clear solution can be completely inactive due to protein denaturation from temperature excursions, light exposure, or age beyond 28 days. The only reliable indicator is response: if you previously experienced sleep depth improvement and it suddenly stops despite consistent dosing and timing, potency loss is likely. Preventive measures include storing reconstituted vials wrapped in foil at 2-8°C, never freezing after reconstitution (ice crystal formation destroys peptide structure), and discarding any vial older than 28 days regardless of appearance. For research applications requiring exact potency verification, HPLC (high-performance liquid chromatography) testing is the gold standard.
Possibly, but efficacy is reduced in individuals with chronically disrupted circadian rhythms. These peptides amplify the endogenous nocturnal GH pulse, which is regulated by the suprachiasmatic nucleus (SCN) and occurs during the circadian night — not simply during sleep. Night shift workers experience circadian misalignment where their sleep period (during daylight hours) conflicts with their biological night (when GH pulses naturally occur). Administering peptides 30-60 minutes before daytime sleep may still enhance slow-wave sleep depth, but the effect is typically 30-50% less pronounced than in individuals sleeping during their circadian night. Rotating shift schedules make consistent dosing nearly impossible.
CJC-1295 no DAC alone increases the amplitude of each GH pulse by sensitising GHRH receptors, but without a concurrent secretagogue stimulus (like Ipamorelin), the pulse frequency and total GH output remain limited. Ipamorelin alone stimulates GH release through ghrelin receptor activation, but without GHRH receptor priming, the magnitude of each pulse is blunted. Clinical studies comparing monotherapy to combination therapy found that CJC-1295 + Ipamorelin produces 2.5-4× greater peak GH levels and more consistent slow-wave sleep enhancement than either peptide used individually at equivalent total doses. The synergy is receptor-level, not additive.